Academic Journal
Q2Clinical and Translational Oncology
About Clinical and Translational Oncology
Clinical and Translational Oncology is a scholarly journal published by Springer Science and Business Media Deutschland GmbH. SCImago 2025 lists it in Q2, with an SJR of 0.833 and H-index of 69.
Coverage: 2000-2026. Research categories: Medicine (miscellaneous) (Q2); Oncology (Q2); Cancer Research (Q3).
Verified field sources
- Journal Impact Factor: 2.7 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Impact Factor year: 2025 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Editor(s): Mariano Provencio MD, PhD (Editor-in-Chief) — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
Source-backed journal facts
Topics in published research
Cancer Immunotherapy and Biomarkers; Lung Cancer Treatments and Mutations; Breast Cancer Treatment Studies; Lung Cancer Diagnosis and Treatment; Lung Cancer Research Studies; Colorectal Cancer Treatments and Studies.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
4,690.00 USD; 3,690.00 EUR; 2,990.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Thanks to reviewers 2021
2022-03 · DOI: 10.1007/s12094-022-02789-9MiR-590 suppresses the progression of non-small cell lung cancer by regulating YAP1 and Wnt/β-catenin signaling
X. Hao, A. Su
2022-03 · DOI: 10.1007/s12094-021-02713-7Human umbilical cord mesenchymal stem cell-derived exosomes carrying hsa-miRNA-128-3p suppress pancreatic ductal cell carcinoma by inhibiting Galectin-3
X. Xie, J. Ji, X. Chen, W. Xu et al.
2022-03 · DOI: 10.1007/s12094-021-02705-7Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
P. García-Alfonso, M. Saiz-Rodríguez, R. Mondéjar, J. Salazar et al.
2022-03 · DOI: 10.1007/s12094-021-02708-4Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer
H. Kim, Y. J. Heo, Y. A. Cho, S. Y. Kang et al.
2022-03 · DOI: 10.1007/s12094-021-02714-6Identification of a novel cancer microbiome signature for predicting prognosis of human breast cancer patients
A. W. Mao, H. Barck, J. Young, A. Paley et al.
2022-03 · DOI: 10.1007/s12094-021-02725-3PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors
H. Chen, H. Liu, J. Ai, X. Du et al.
2022-03 · DOI: 10.1007/s12094-021-02723-5Future care for long-term cancer survivors: towards a new model
M. Provencio, N. Romero, J. Tabernero, R. Vera et al.
2022-02 · DOI: 10.1007/s12094-021-02696-5Linezolid-induced thrombocytopenia in patients with acute myeloid leukemia: a matched case–control study
Can Chen, Yiwei Li, Jingdi Yu, Shenxian Qian et al.
2022-03 · DOI: 10.1007/s12094-021-02711-9High-dose-rate plesiotherapy with customized molds in non-melanoma skin cancer: efficacy and safety at 10 years—single institution experience
I. Membrive Conejo, O. Pera Cegarra, P. Foro Arnalot, A. Reig Castillejo et al.
2022-03 · DOI: 10.1007/s12094-021-02718-2Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab
H. Ueki, N. Hinata, K. Kitagawa, T. Hara et al.
2022-03 · DOI: 10.1007/s12094-021-02717-3Quality indicators and excellence requirements for a multidisciplinary lung cancer tumor board by the Spanish Lung Cancer Group
M. Guirado, A. Sanchez-Hernandez, L. Pijuan, C. Teixido et al.
2022-03 · DOI: 10.1007/s12094-021-02712-8Traditional Chinese medicine reverses cancer multidrug resistance and its mechanism
J. Wei, Z. Liu, J. He, Q. Liu et al.
2022-03 · DOI: 10.1007/s12094-021-02716-4The TRIM proteins in cancer: from expression to emerging regulatory mechanisms
A. Mohammadi, M. S. Pour Abbasi, S. Khorrami, S. Khodamoradi et al.
2022-03 · DOI: 10.1007/s12094-021-02715-5SEOR SBRT-SG stereotactic body radiation therapy consensus guidelines for non-spine bone metastasis
F. Lopez-Campos, J. Cacicedo, F. Couñago, R. García et al.
2022-02 · DOI: 10.1007/s12094-021-02695-6Multidisciplinary consensus on the criteria for fertility preservation in cancer patients
A. Santaballa, C. Márquez-Vega, Á. Rodríguez-Lescure, Á. Rovirosa et al.
2022-02 · DOI: 10.1007/s12094-021-02699-2Inhibitory effect of polyphenols (phenolic acids, lignans, and stilbenes) on cancer by regulating signal transduction pathways: a review
A. Hazafa, M. O. Iqbal, U. Javaid, M. B. K. Tareen et al.
2022-03 · DOI: 10.1007/s12094-021-02709-3Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance
M. Murali, A. R. Kumar, B. Nair, K. Pavithran et al.
2022-03 · DOI: 10.1007/s12094-021-02707-5Low-dose radiation therapy for hand osteoarthritis: shaking hands again?
B. Álvarez, A. Montero, R. Alonso, J. Valero et al.
2022-03 · DOI: 10.1007/s12094-021-02710-wBiological functions and potential therapeutic applications of huntingtin-associated protein 1: progress and prospects
X. Zhao, A. Chen, Z. Wang, Xiao-Han Xu et al.
2022-02 · DOI: 10.1007/s12094-021-02702-wReviews
Community Reviews
Version History
October 2, 2026 at 8:41 pm
October 2, 2026